详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study

59| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. [2]Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou, China. [3]State Key Laboratory of Systems Medicine for Cancer, School of Biomedical Engineering, Institute of Medical Robotics and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China. [4]Department of Obstetrics and Gynecology, Shanghai Key Laboratory of Gynecologic Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. [5]Division of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. [6]Office of Cancer Center, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. [7]Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. [8]The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. [9]Department of Gastrointestinal Surgery, Sichuan Cancer Hospital, Chengdu, China. [10]Department of General Surgery, Fenghua People's Hospital, Ningbo, China. [11]Department of Gastroenterology, Tiantai People's Hospital, Taizhou, China. [12]Department of Gastroenterology, Xinchang People's Hospital, Shaoxing, China. [13]Department of General Surgery, Daishan People's Hospital, Zhoushan, China.

出处：

DOI：

ISSN：

摘要：

Metabolic biomarkers are expected to decode the phenotype of gastric cancer (GC) and lead to high-performance blood tests towards GC diagnosis and prognosis. We attempted to develop diagnostic and prognostic models for GC based on plasma metabolic information.We conducted a large-scale, multicentre study comprising 1944 participants from 7 centres in retrospective cohort and 264 participants in prospective cohort. Discovery and verification phases of diagnostic and prognostic models were conducted in retrospective cohort through machine learning and Cox regression of plasma metabolic fingerprints (PMFs) obtained by nanoparticle-enhanced laser desorption/ionisation-mass spectrometry (NPELDI-MS). Furthermore, the developed diagnostic model was validated in prospective cohort by both NPELDI-MS and ultra-performance liquid chromatography-MS (UPLC-MS).We demonstrated the high throughput, desirable reproducibility and limited centre-specific effects of PMFs obtained through NPELDI-MS. In retrospective cohort, we achieved diagnostic performance with areas under curves (AUCs) of 0.862-0.988 in the discovery (n=1157 from 5 centres) and independent external verification dataset (n=787 from another 2 centres), through 5 different machine learning of PMFs, including neural network, ridge regression, lasso regression, support vector machine and random forest. Further, a metabolic panel consisting of 21 metabolites was constructed and identified for GC diagnosis with AUCs of 0.921-0.971 and 0.907-0.940 in the discovery and verification dataset, respectively. In the prospective study (n=264 from lead centre), both NPELDI-MS and UPLC-MS were applied to detect and validate the metabolic panel, and the diagnostic AUCs were 0.855-0.918 and 0.856-0.916, respectively. Moreover, we constructed a prognosis scoring system for GC in retrospective cohort, which can effectively predict the survival of GC patients.We developed and validated diagnostic and prognostic models for GC, which also contribute to advanced metabolic analysis towards diseases, including but not limited to GC.© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

基金：

语种：

高被引：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区胃肠肝病学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区胃肠肝病学

JCR分区：

出版当年[2023]版：

Q1 GASTROENTEROLOGY & HEPATOLOGY

最新[2023]版：

Q1 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 23.1 最新[2023版] 24.5 最新五年平均 23.1 出版当年[2023版] 24.5 出版当年五年平均 24.5 出版前一年[2022版]

第一作者：

第一作者机构： [1]Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. [2]Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. [2]Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou, China. [3]State Key Laboratory of Systems Medicine for Cancer, School of Biomedical Engineering, Institute of Medical Robotics and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China. [4]Department of Obstetrics and Gynecology, Shanghai Key Laboratory of Gynecologic Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. [5]Division of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. [6]Office of Cancer Center, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study $(function () { $("[data-toggle='tooltip']").tooltip(); });

文献详情

Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study